Fallopian Tube Cancer - Pipeline Review, H2 2016

 


Get this Report



PayPal Verified Vendor

Rating

4.9 Star Rating for report Fallopian Tube Cancer - Pipeline Review, H2 2016
4.9 / 5 stars rating
Pages: 677
Price: $2000.00

Some of our Clients

Some Research and Expert Clients

Abstract

 
Fallopian tube cancer is also called tubal cancer. It develops in the fallopian tubes, which serve as a connection between the ovaries and the uterus. It occurs very rarely. The common symptoms of fallopian tube cancer may include abnormal vaginal bleeding, especially after menopause, abdominal pain or a feeling of pressure in the abdomen, abnormal vaginal discharge that is white, clear or pinkish and a pelvic mass at the time of diagnosis, which is present in up to two-thirds of patients. Usually, cancer metastasizes from other parts of the body such as the ovaries or endometrium to the fallopian tubes. Fallopian tube cancer treatment depends on age, the desire to have children, type and stage of the tumor. It usually involves surgery followed by chemotherapy.  

Description

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fallopian Tube Cancer - Pipeline Review, H2 2016, provides an overview of the Fallopian Tube Cancer (Oncology) pipeline landscape.

Fallopian tube cancer is also called tubal cancer. It develops in the fallopian tubes, which serve as a connection between the ovaries and the uterus. It occurs very rarely. The common symptoms of fallopian tube cancer may include abnormal vaginal bleeding, especially after menopause, abdominal pain or a feeling of pressure in the abdomen, abnormal vaginal discharge that is white, clear or pinkish and a pelvic mass at the time of diagnosis, which is present in up to two-thirds of patients. Usually, cancer metastasizes from other parts of the body such as the ovaries or endometrium to the fallopian tubes. Fallopian tube cancer treatment depends on age, the desire to have children, type and stage of the tumor. It usually involves surgery followed by chemotherapy.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC8870IDBColorectal Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8862IDBPancreatic Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8864IDBNon-Small Cell Lung Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8866IDBOvarian Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8868IDBMelanoma - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8869IDBAcute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - P...Dec 2016
Report... 05IB-GMDHC8871IDBBreast Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8860IDBProstate Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8844IDBMultiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8816IDBKidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2016Dec 2016

Report Source Information

Supplied by: Research and Experts 
Date Published: 2016-10-26 

Report: Fallopian Tube Cancer - Pipeline Review, H2 2016

 

Contents

Table of Contents
Table of Contents 2
Introduction 6
Fallopian Tube Cancer Overview 7
Therapeutics Development 8
Fallopian Tube Cancer - Therapeutics under Development by Companies 10
Fallopian Tube Cancer - Therapeutics under Investigation by Universities/Institutes 16
Fallopian Tube Cancer - Pipeline Products Glance 17
Fallopian Tube Cancer - Products under Development by Companies 21
Fallopian Tube Cancer - Products under Investigation by Universities/Institutes 27
Fallopian Tube Cancer - Companies Involved in Therapeutics Development 28
Fallopian Tube Cancer - Therapeutics Assessment 106
Drug Profiles 133
Fallopian Tube Cancer - Discontinued Products 657
Fallopian Tube Cancer - Product Development Milestones 658
Appendix 664
 

List of Tables

List of Tables
Number of Products under Development for Fallopian Tube Cancer, H2 2016 20
Number of Products under Development for Fallopian Tube Cancer - Comparative Analysis, H2 2016 21
Number of Products under Development by Companies, H2 2016 23
Number of Products under Development by Companies, H2 2016 (Contd..1) 24
Number of Products under Development by Companies, H2 2016 (Contd..2) 25
Number of Products under Development by Companies, H2 2016 (Contd..3) 26
Number of Products under Development by Companies, H2 2016 (Contd..4) 27
Number of Products under Investigation by Universities/Institutes, H2 2016 28
Comparative Analysis by Late Stage Development, H2 2016 29
Comparative Analysis by Clinical Stage Development, H2 2016 30
Comparative Analysis by Early Stage Development, H2 2016 31
Comparative Analysis by Unknown Stage Development, H2 2016 32
Products under Development by Companies, H2 2016 33
Products under Development by Companies, H2 2016 (Contd..1) 34
Products under Development by Companies, H2 2016 (Contd..2) 35
Products under Development by Companies, H2 2016 (Contd..3) 36
Products under Development by Companies, H2 2016 (Contd..4) 37
Products under Development by Companies, H2 2016 (Contd..5) 38
Products under Investigation by Universities/Institutes, H2 2016 39
Fallopian Tube Cancer - Pipeline by AbbVie Inc, H2 2016 40
Fallopian Tube Cancer - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 41
Fallopian Tube Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 42
Fallopian Tube Cancer - Pipeline by Aduro BioTech, Inc., H2 2016 43
Fallopian Tube Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2016 44
Fallopian Tube Cancer - Pipeline by Amgen Inc., H2 2016 45
Fallopian Tube Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2016 46
Fallopian Tube Cancer - Pipeline by AstraZeneca Plc, H2 2016 47
Fallopian Tube Cancer - Pipeline by Atara Biotherapeutics, Inc., H2 2016 48
Fallopian Tube Cancer - Pipeline by Bayer AG, H2 2016 49
Fallopian Tube Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 50
Fallopian Tube Cancer - Pipeline by Boston Biomedical, Inc., H2 2016 51
Fallopian Tube Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2016 52
Fallopian Tube Cancer - Pipeline by Celsion Corporation, H2 2016 53
Fallopian Tube Cancer - Pipeline by Cerulean Pharma, Inc., H2 2016 54
Fallopian Tube Cancer - Pipeline by Clovis Oncology, Inc., H2 2016 55
Fallopian Tube Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2016 56
Fallopian Tube Cancer - Pipeline by CTI BioPharma Corp., H2 2016 57
Fallopian Tube Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016 58
Fallopian Tube Cancer - Pipeline by EirGenix Inc., H2 2016 59
Fallopian Tube Cancer - Pipeline by Eisai Co., Ltd., H2 2016 60
Fallopian Tube Cancer - Pipeline by Eli Lilly and Company, H2 2016 61
Fallopian Tube Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2016 62
Fallopian Tube Cancer - Pipeline by Exelixis, Inc., H2 2016 63
Fallopian Tube Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 64
Fallopian Tube Cancer - Pipeline by Galena Biopharma, Inc., H2 2016 65
Fallopian Tube Cancer - Pipeline by Ganymed Pharmaceuticals AG, H2 2016 66
Fallopian Tube Cancer - Pipeline by Gene Techno Science Co., Ltd., H2 2016 67
Fallopian Tube Cancer - Pipeline by Genentech, Inc., H2 2016 68
Fallopian Tube Cancer - Pipeline by Genor BioPharma Co Ltd, H2 2016 69
Fallopian Tube Cancer - Pipeline by Glycotope GmbH, H2 2016 70
Fallopian Tube Cancer - Pipeline by Gradalis Inc., H2 2016 71
Fallopian Tube Cancer - Pipeline by Ignyta, Inc., H2 2016 72
Fallopian Tube Cancer - Pipeline by Immune Design Corp., H2 2016 73
Fallopian Tube Cancer - Pipeline by ImmunoGen, Inc., H2 2016 74
Fallopian Tube Cancer - Pipeline by Immunovaccine, Inc., H2 2016 75
Fallopian Tube Cancer - Pipeline by Incyte Corporation, H2 2016 76
Fallopian Tube Cancer - Pipeline by Innate Pharma S.A., H2 2016 77
Fallopian Tube Cancer - Pipeline by Johnson & Johnson, H2 2016 78
Fallopian Tube Cancer - Pipeline by Juno Therapeutics Inc., H2 2016 79
Fallopian Tube Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 80
Fallopian Tube Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016 81
Fallopian Tube Cancer - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 82
Fallopian Tube Cancer - Pipeline by Mabion SA, H2 2016 83
Fallopian Tube Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H2 2016 84
Fallopian Tube Cancer - Pipeline by Mateon Therapeutics Inc, H2 2016 85
Fallopian Tube Cancer - Pipeline by MedImmune, LLC, H2 2016 86
Fallopian Tube Cancer - Pipeline by Medivation, Inc., H2 2016 87
Fallopian Tube Cancer - Pipeline by Merck & Co., Inc., H2 2016 88
Fallopian Tube Cancer - Pipeline by Merck KGaA, H2 2016 89
Fallopian Tube Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 90
Fallopian Tube Cancer - Pipeline by MolMed S.p.A., H2 2016 91
Fallopian Tube Cancer - Pipeline by Mycenax Biotech Inc., H2 2016 92
Fallopian Tube Cancer - Pipeline by Novartis AG, H2 2016 93
Fallopian Tube Cancer - Pipeline by OBI Pharma, Inc., H2 2016 94
Fallopian Tube Cancer - Pipeline by Oncobiologics, Inc., H2 2016 95
Fallopian Tube Cancer - Pipeline by Oncolix, Inc., H2 2016 96
Fallopian Tube Cancer - Pipeline by Oncolytics Biotech Inc., H2 2016 97
Fallopian Tube Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2016 98
Fallopian Tube Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 99
Fallopian Tube Cancer - Pipeline by Oxford BioMedica Plc, H2 2016 100
Fallopian Tube Cancer - Pipeline by Pharma Mar, S.A., H2 2016 101
Fallopian Tube Cancer - Pipeline by PsiOxus Therapeutics Limited, H2 2016 102
Fallopian Tube Cancer - Pipeline by Quest PharmaTech Inc., H2 2016 103
Fallopian Tube Cancer - Pipeline by Richter Gedeon Nyrt., H2 2016 104
Fallopian Tube Cancer - Pipeline by Samyang Holdings Corporation, H2 2016 105
Fallopian Tube Cancer - Pipeline by Sanofi Pasteur SA, H2 2016 106
Fallopian Tube Cancer - Pipeline by Sellas Inc, H2 2016 107
Fallopian Tube Cancer - Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H2 2016 108
Fallopian Tube Cancer - Pipeline by Sotio a.s., H2 2016 109
Fallopian Tube Cancer - Pipeline by TapImmune Inc., H2 2016 110
Fallopian Tube Cancer - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016 111
Fallopian Tube Cancer - Pipeline by Tesaro, Inc., H2 2016 112
Fallopian Tube Cancer - Pipeline by TetraLogic Pharmaceuticals, H2 2016 113
Fallopian Tube Cancer - Pipeline by Tyrogenex, Inc., H2 2016 114
Fallopian Tube Cancer - Pipeline by Vascular Biogenics Ltd., H2 2016 115
Fallopian Tube Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2016 116
Fallopian Tube Cancer - Pipeline by Vyriad Inc, H2 2016 117
Assessment by Monotherapy Products, H2 2016 118
Number of Products by Stage and Target, H2 2016 120
Number of Products by Stage and Mechanism of Action, H2 2016 131
Number of Products by Stage and Route of Administration, H2 2016 142
Number of Products by Stage and Molecule Type, H2 2016 144
Fallopian Tube Cancer - Dormant Projects, H2 2016 665
Fallopian Tube Cancer - Dormant Projects (Contd..1), H2 2016 666
Fallopian Tube Cancer - Dormant Projects (Contd..2), H2 2016 667
Fallopian Tube Cancer - Dormant Projects (Contd..3), H2 2016 668
Fallopian Tube Cancer - Discontinued Products, H2 2016 669
 

List of Figures

List of Figures
Number of Products under Development for Fallopian Tube Cancer, H2 2016 20
Number of Products under Development for Fallopian Tube Cancer - Comparative Analysis, H2 2016 21
Number of Products under Development by Companies, H2 2016 22
Number of Products under Investigation by Universities/Institutes, H2 2016 28
Comparative Analysis by Late Stage Development, H2 2016 29
Comparative Analysis by Clinical Stage Development, H2 2016 30
Comparative Analysis by Early Stage Products, H2 2016 31
Assessment by Monotherapy Products, H2 2016 118
Number of Products by Top 10 Targets, H2 2016 119
Number of Products by Stage and Top 10 Targets, H2 2016 119
Number of Products by Top 10 Mechanism of Actions, H2 2016 130
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 130
Number of Products by Top 10 Routes of Administration, H2 2016 141
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 141
Number of Products by Top 10 Molecule Types, H2 2016 143
Number of Products by Stage and Top 10 Molecule Types, H2 2016 143
 

Scope


- The pipeline guide provides a snapshot of the global therapeutic landscape of Fallopian Tube Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Fallopian Tube Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Fallopian Tube Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Fallopian Tube Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Fallopian Tube Cancer (Oncology)

 

Highlights

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fallopian Tube Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Fallopian Tube Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fallopian Tube Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Fallopian Tube Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Unknown stages are 1, 2, 12, 51, 25, 1, 1, 8 and 1 respectively for Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 3 and 1 molecules, respectively for Fallopian Tube Cancer.

Fallopian Tube Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

 

Classification

Language Code: EN 
Region: Global 
Report Type: Market Report 
Industry: Life Sciences 
Sector: Oncology 
Pages: 677 

Companies Featured

AbbVie Inc Acetylon Pharmaceuticals, Inc. Adaptimmune Therapeutics Plc Aduro BioTech, Inc. Advenchen Laboratories, LLC Amgen Inc. Astex Pharmaceuticals, Inc. AstraZeneca Plc Atara Biotherapeutics, Inc. Bayer AG Boehringer Ingelheim GmbH Boston Biomedical, Inc. Celldex Therapeutics, Inc. Celsion Corporation Cerulean Pharma, Inc. Clovis Oncology, Inc. Critical Outcome Technologies Inc. CTI BioPharma Corp. Dr. Reddy's Laboratories Limited EirGenix Inc. Eisai Co., Ltd. Eli Lilly and Company Esperance Pharmaceuticals, Inc. Exelixis, Inc. F. Hoffmann-La Roche Ltd. Galena Biopharma, Inc. Ganymed Pharmaceuticals AG Gene Techno Science Co., Ltd. Genentech, Inc. Genor BioPharma Co Ltd Glycotope GmbH Gradalis Inc. Ignyta, Inc. Immune Design Corp. ImmunoGen, Inc. Immunovaccine, Inc. Incyte Corporation Innate Pharma S.A. Johnson & Johnson Juno Therapeutics Inc. Karyopharm Therapeutics, Inc. Kyowa Hakko Kirin Co., Ltd. Lee's Pharmaceutical Holdings Limited Mabion SA MabVax Therapeutics Holdings, Inc. Mateon Therapeutics Inc MedImmune, LLC Medivation, Inc. Merck & Co., Inc. Merck KGaA Millennium Pharmaceuticals Inc MolMed S.p.A. Mycenax Biotech Inc. Novartis AG OBI Pharma, Inc. Oncobiologics, Inc. Oncolix, Inc. Oncolytics Biotech Inc. OncoMed Pharmaceuticals, Inc. Ono Pharmaceutical Co., Ltd. Oxford BioMedica Plc Pharma Mar, S.A. PsiOxus Therapeutics Limited Quest PharmaTech Inc. Richter Gedeon Nyrt. Samyang Holdings Corporation Sanofi Pasteur SA Sellas Inc Shenzen SiBiono GeneTech Co., Ltd. Sotio a.s. TapImmune Inc. Tara Immuno-Oncology Therapeutics LLC Tesaro, Inc. TetraLogic Pharmaceuticals Tyrogenex, Inc. Vascular Biogenics Ltd. VentiRx Pharmaceuticals, Inc. Vyriad Inc

 

Reasons to buy this report


- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Fallopian Tube Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Fallopian Tube Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC8870IDBColorectal Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8862IDBPancreatic Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8864IDBNon-Small Cell Lung Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8866IDBOvarian Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8868IDBMelanoma - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8869IDBAcute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - P...Dec 2016
Report... 05IB-GMDHC8871IDBBreast Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8860IDBProstate Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8844IDBMultiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8816IDBKidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2016Dec 2016

Fallopian Tube Cancer - Pipeline Review, H2 2016

Report 05IB-GMDHC8595IDB has a rating of 95.8 percent
Figure of merit assessment for report 05IB-GMDHC8595IDB

Relevance Rating

The Research and Experts relevance ranting consists of a set of figure of merit (FOM) values that are provided as an indication of the value of the report in the current economic environment.

These FOM values cannot take into account the reason for the clients interest in a report and therefore the client should view these FOM values only as a visual guide. The FOM scores are based on

market interest - how often the report is viewed or purchased,
elapsed time - time since the report was published,
report detail - amount of detail in the report (pages, figures, images, comments etc.) and
price - the price of the report.


Regional Information

Taxonomy

Branch ID: 1591

Taxonomy Location

The taxonomy on the left shows the ancestors of the Global node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Global

The global economy is the economy of all the world's countries. The total world population now stands at over 7 billion and the global unemployment rate is 9% with approximately half the world's population paid less than $2 a day. 

The global economy is picking up again after five years of uncertaintity and slow economic growth. The IMF is predicting global growth of 3.7% in 2014 rising to 3.9% in 2015. However, much uncertainity remains. Low inflation in developed economies means that these economies take longer to deal with debt burdens and are at increases risk of deflation. 

The second half of 2013 saw growth in the US and European economies (particularly UK, Germany and France).  

Growth in the US has been helped by cheaper energy from fracking , renewables and more oil and gas exploration. This cheaper energy is bring manufacturing jobs back to the US and helping to boost domestic demand. Recent winter weather conditions have hampered growth in the construction sector and have slowed demand in the construction equipment sector which saw exports drop by 25% in 2013. Growth should pick up in this sector with continued federal investment in infrastructure, new residential house builds and refurbishment and the energy boom.

In Europe growth is expected to be uneven with growth being slow in stressed economies such as Portugal and Greece but confidence picking up in UK, Ireland and even Spain showing some improvement.

Developing economies such as China and India will continue to have strong growth in 2014 and 2015. China has benefitted from increased investment with the Chinese govenment now focused on quality growth of 7.5% in 2014. India which is less reliant on exports expects growth of 5.4% in 2014 and 6.4% in 2015.

Much uncertainity still remains in the global economy with greater optimism needed to stabilise growth.

Links

World Bank

IMF (International Monetary Fund)

 

 

Zones

Regional zones

 

Country

Countries

 

Industry Sector Information

Taxonomy

Branch ID: 7174

Taxonomy Location

The taxonomy on the left shows the ancestors of the Oncology node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Oncology

Oncology

 

Healthcare

The healthcare industry is changing rapidly due to changes in legislation (US Affordable Healthcare Act),  advances in IT and more pressures on governments and healthcare providers due to rising costs. 

According to a recent report by the OECD healthcare spending has fallen in one third of OECD member states due to the credit crunch and members are facing up to the challenge of providing greater care with fewer resources. Spending on healthcare has increased in Japan, Israel and Korea while it has dropped dramatically in Greece and Ireland.

Useful Links

World Health Organisation 

American Healthcare Association

The British Healthcare Business Intelligence Association

OECD, Health Policies and Data

Healthcare

Life Sciences

The Life Sciences industry includes biotechnology, healthcare, pharmaceuticals, medical devices and diagnostics. The industry is dominated by US companies requiring considerable investment in research and development to stay competitive.  While US companies dominate this space, competition is emerging from smaller companies in Europe and Asia. 

Companies trying to stay competitive or enter new markets in life sciences consult our reports. For example, Plimsoll, in their recent review of global antibiotic manufacturers have reviewed 150 of the largest manufacturers including analysis of  ANTIBIOTICE SA, BAYER HEALTHCARE MANUFACTURING SRL and CIPLA LTD. 

Our reports are a requirement for companies looking for the best competitive intelligence in the life sciences sector providing information on market size, rankings, best trading partners and financial analysis. 

Useful Links

Analytical Life Sciences and Diagnostics Association

German Life Sciences Association

 

Life Sciences

Industry

Industries

 

 

Buy: Fallopian Tube Cancer - Pipeline Review, H2 2016

 

Item Code: 05IB-GMDHC8595IDB

 
Licence: Single User
Price: $2000.00
 
VAT: 0.0% 
Total: $2000.00 

Feedback

Return to Research and Experts

Page created and rendered - Cache updated [3.63295s]

--